

Table 4.26

## Cancer of the Female Breast(In Situ)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2012-2016  
Females by Race

Histology <sup>a</sup>	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native <sup>b</sup>		Hispanic <sup>c</sup>	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Adenocarcinoma <sup>d</sup>	111,997	99.9%	85,458	99.9%	13,652	99.9%	10,843	99.9%	345	99.7%	12,322	99.9%
Adenocarcinoma <i>in situ</i> , NOS (8140/2)	-	-	-	-	-	-	-	-	-	-	-	-
Ductal carcinoma <i>in situ</i> <sup>e</sup>	91,147	81.3%	68,476	80.1%	11,616	85.0%	9,542	87.9%	306	88.4%	10,110	81.9%
Cribriform carcinoma <i>in situ</i> (8201/2)	9,938	8.9%	7,393	8.6%	1,262	9.2%	1,111	10.2%	25	7.2%	1,076	8.7%
Ductal carcinoma <i>in situ</i> , solid type(8230/2)	8,013	7.1%	6,193	7.2%	870	6.4%	832	7.7%	27	7.8%	766	6.2%
Ductal carcinoma <i>in situ</i> , NOS (8500/2)	25,679	22.9%	19,643	23.0%	3,129	22.9%	2,396	22.1%	108	31.2%	2,820	22.9%
Comedocarcinoma <i>in situ</i> (8501/2)	8,359	7.5%	6,352	7.4%	954	7.0%	931	8.6%	32	9.2%	910	7.4%
Ductal carcinoma <i>in situ</i> papillary(8503/2)	1,563	1.4%	1,034	1.2%	323	2.4%	171	1.6%	-	-	204	1.7%
Noninfiltrating intracystic carcinoma(8504/2)	317	0.3%	210	0.2%	51	0.4%	52	0.5%	-	-	36	0.3%
Ductal carcinoma <i>in situ</i> micropapillary(8507/2)	1,555	1.4%	1,187	1.4%	221	1.6%	125	1.2%	-	-	167	1.4%
Intraductal with other types of carcinoma <i>in situ</i> (8523/2)	35,468	31.6%	26,282	30.7%	4,786	35.0%	3,875	35.7%	106	30.6%	4,105	33.3%
Lobular carcinoma <i>in situ</i> (8520/2-8521/2, 8524/2)	16,547	14.8%	13,567	15.9%	1,538	11.3%	970	8.9%	34	9.8%	1,777	14.4%
Lobular carcinoma <i>in situ</i> , NOS (8520/2)	16,531	14.7%	13,558	15.9%	1,533	11.2%	969	8.9%	33	9.5%	1,775	14.4%
Lobular CIS <sup>f</sup> with other CIS <sup>f</sup> (8524/2)	16	0.0%	-	-	-	-	-	-	-	-	-	-
Intraductal and lobular <i>in situ</i> carcinoma (8522/2)	3,633	3.2%	2,929	3.4%	408	3.0%	250	2.3%	-	-	353	2.9%
Other adenocarcinomas <sup>g</sup>	661	0.6%	480	0.6%	89	0.7%	79	0.7%	-	-	82	0.7%
Other <i>in situ</i> histologies <sup>h</sup>	115	0.1%	80	0.1%	-	-	-	-	-	-	16	0.1%
Total	112,112	100.0%	85,538	100.0%	13,667	100.0%	10,854	100.0%	346	100.0%	12,338	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

<sup>d</sup> Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>e</sup> Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

<sup>f</sup> Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.

<sup>g</sup> CIS = Carcinoma *in situ*.

<sup>h</sup> Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

<sup>i</sup> Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.